Polycystic ovary syndrome (PCOS) is a common disease in women of the reproductive age. Patients with PCOS are at high risk for metabolic disorders, such as insulin resistance (IR), hyperinsulinemia (HI), impaired glucose tolerance (IGT), type 2 diabetes, obesity and arterial hypertension. The discovery of a defect in the inositol phosphoglycan second messenger pathway could be at the basis of the HI, via an impairment of the post-receptor insulin-induced signal, it opens the way for new therapeutical strategies for PCOS. The objective of this study is to assess the effect of myo-inositol (MI) with folic acid (FC) by endocrine-metabolic parameters and body composition of patients with PCOS. 
Seventy-eight patients (26,4±4,6 years) diagnosed with PCOS according to the Rotterdam criteria were enrolled in this study. Patients were treated for 6 months with MI 4g + folic acid (FA) 400µg daily. Menstrual cycles, body mass index (BMI) and serum levels of the anti-mullerian  hormone (AMH), free testosterone (fT), total testosterone (tT), index of free androgens (FAI), androstendione (A), dihydrotestosterone (DHT), 17-OH-progesterone (17-OH), sex hormone-binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), progesterone were measured at baseline and after 3 and 6 months therapy. The serum levels of glucose and insulin during the standard oral glucose tolerance test (OGTT) were measured at baseline and after 6 months MI. The body composition measurements, including total body fat (%) (BF), android and gynoid fat (%), visceral adipose tissue (VAT) mass and volume were assessed by dual–energy X-ray absorptiometry scan (DXA) at baseline and 6 months of treatment.
Findings showed that MI use for 6 months was significantly associated with a decrease in the mean level of AMH by 27,7%, LH – 22%, tT – 18%, fT- 28%, A- 15%, 17-OH – 36,6%, FAI – 40,5%, leptin – 38,5% and an increase in the mean level of SHBG by 25% (p<0,001). Ml supplementation significantly reduced the frequency of hyperinsulinemia (HI) from 48% to 22,8% (p=0,004) and of impaired glucose tolerance (IGT) – from 18,7% to 3,5% (p<0,001). The mean of BMI reduced by 8,6% after treatment  (р<0,001).  The percentage of women with normal BMI (18,5-24,9%) increased from 75,6% to 89,5% (р≤0,001). However the BF in women with normal BMI reduced from 64,7% to 39% (р≤0,001). The average meanings of BF, gynoid and android fat, VAT mass and volume reduced by 11,5%,  16% and 10%, 38,4% and 33,2 (р≤0,001). The menstrual function restoration was observed in 38,6%.
The obtained data indicates that MI significantly reduces hyperandrogenism, HI, ITG and body fat, mainly due to VAT, that leads to the regulation of menstrual function in every third woman with PCOS.

MYO-INOSITOL EFFECTS ON METABOLIC AND HORMONAL PARAMETERS AND BODY COMPOSITION IN WOMEN WITH POLYCYSTIC OVARY SYNDROME